Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Trial details
- Registry ID
- NCT07484217
- Drugs studied
- Solriamfetol 150 MG
TrialRedline tracks 25 clinical trials sponsored by Axsome Therapeutics, Inc.: 22 Phase 3, 1 Phase 2 / 3, 2 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Addressing Dementia Via Agitation-Centered EvaluationNCT03226522 | AXS-05, Bupropion | Completed | 2020-04-17Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)NCT03881852 | AXS-12 (Reboxetine) | Completed | 2019-11-27Actual |
| Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)NCT04634669 | AXS-05 (dextromethorphan-bupropion) | Terminated | 2022-02-18Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2027-05-01Day | AXS-12 (reboxetine)Axsome Therapeutics, Inc. · AXSM | Company-disclosed PDUFA goal dateAnnounced review target | cataplexy in narcolepsy | Open original sourceRead source excerptAxsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy FDA sets PDUFA target action date of May 1, 2027 First seen: 25 Sep 2026 · Evidence last checked: 25 Sep 2026 |
| 2027-05-01Day | AXS-12 (reboxetine)Axsome Therapeutics, Inc. · AXSM | Company-disclosed PDUFA goal dateAnnounced review target | cataplexy in narcolepsy | Open original sourceRead source excerptAxsome’s NDA for AXS-12 for the treatment of cataplexy in narcolepsy is currently under review by the FDA. The PDUFA target action date is May 1, 2027. First seen: 02 Nov 2026 · Evidence last checked: 02 Nov 2026 |
Names as written in the registry records.
NCT06878976 · Axsome Therapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Long-term Safety. After: Measure: Time from randomization to relapse of binge eating in the RW segment.
Before: 300 participants (planned). After: 236 participants (planned).
Before: Dec 2026. After: Dec 2027.
NCT06413433 · Axsome Therapeutics, Inc.
Before: Dec 2025. After: Dec 2026.
NCT04163185 · Axsome Therapeutics, Inc.
Before: 23 Mar 2020. After: 16 Mar 2020.
NCT04634669 · Axsome Therapeutics, Inc.
Before: Completed. After: Terminated.
NCT05550207 · Axsome Therapeutics, Inc.
Before: 16 Oct 2024. After: 27 Nov 2024.